Norges Bank
ACRS icon

Norges Bank’s Aclaris Therapeutics ACRS Stock Holding History

Norges Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-33,170
Closed -$900K – 2139
2016
Q4 		$900K Hold
33,170
– – ﹤0.01% 2065
2016
Q3 		$811K Sell
33,170
-16,830
-34% -$357K ﹤0.01% 2072
2016
Q2 		$924K Hold
50,000
– – ﹤0.01% 2076
2016
Q1 		$948K Hold
50,000
– – ﹤0.01% 2068
2015
Q4 		$1.35M Buy
+50,000
New +$974K ﹤0.01% 2080

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank's ACRS Position: Q1 2017 in Review

Norges Bank sold out of Aclaris Therapeutics (ACRS) in Q1 2017, closing a stake of 33,170 shares — an estimated $900K sold.

Norges Bank first reported a position in ACRS in Q4 2015 and held it in 5 quarters. The position peaked at $1.35M in Q4 2015. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2017.

  • Norges Bank reported no remaining Aclaris Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Norges Bank sold 33,170 Aclaris Therapeutics shares in Q1 2017, an estimated $900K.
  • Norges Bank first reported a position in Aclaris Therapeutics in Q4 2015 and held it in 5 quarters.
  • Norges Bank's Aclaris Therapeutics position peaked at $1.35M in Q4 2015.
  • 110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2017.

Based on Norges Bank's 13F filing for Q1 2017, filed 10 May 2017.